a decreasing trendp = 0.0916
We observed that over the course of 5 days, LiveSpo DIA30 treatment led to a significant decrease in IL-17 and IL-23 (by 26.62% and 25.13%, with p values of 0.0178 and 0.0256, respectively), a 19.09% ( p = 0.038) reduction in TNF-α signaling and a decreasing trend in IL-6 (8.54%; p = 0.0916) (Fig. 3 A-D).